(RFL) Rafael Holdings, Inc. PESTLE Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RFL) Rafael Holdings, Inc. Complete Analysis Pack
Your Shortcut to Market Insight Starts Here
This Rafael Holdings, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why that matters for strategy and investment. The page includes a real preview/sample of the report so you can assess style and depth; purchase the full version to receive the complete ready-to-use analysis.
Political factors
US FDA oversight for 2 Phase III trials
Rafael Holdings’ CPI-613 (devimistat) sits at a critical FDA gate: the company has 2 pivotal Phase III registrational trials, so U.S. oversight can make or break the path to approval.
Any shift in FDA oncology review standards or timing can delay readouts, add protocol changes, and raise development spend across both studies.
That matters because Phase III trials are the most capital-heavy stage, and even small FDA requests can push timelines by months.
US and Israel cross-border exposure
Rafael Holdings’ U.S. and Israel assets expose it to two policy regimes, so changes in taxes, permits, sanctions, or capital rules can hit operations fast. U.S.-Israel trade topped $50 billion in 2024, so any bilateral friction can affect cross-border flow and investor confidence. Political stability matters in both markets, because security shocks in Israel or policy shifts in the U.S. can disrupt continuity.
New Jersey headquarters and local policy
Rafael Holdings is based in Newark, New Jersey, so state and city policy can move costs fast. New Jersey’s corporate business tax reaches 11.5% on income above $1 million, and permits, zoning, and local incentives can affect both headquarters and real estate assets. Newark’s infrastructure spending and economic-development programs also matter for tenant demand and project timelines.
Healthcare reimbursement policy
Rafael Holdings, Inc.’s drug pipeline still depends on payer and government reimbursement, and oncology prices face heavy pushback from public and private insurers. Medicare covers about 66 million Americans, so policy shifts can quickly change access, uptake, and revenue.
For commercial launch, even strong clinical data is not enough if coding, formulary placement, or prior authorization slows use. The Inflation Reduction Act’s Medicare negotiation path adds more pricing pressure, so future oncology margins may move with reimbursement rules as much as with science.
- Reimbursement drives market access.
- Oncology pricing faces insurer pressure.
- Policy shifts can cut revenue fast.
Commercial real estate zoning and public-use rules
Rafael Holdings, Inc.’s real estate segment includes a commercial office complex with an 800-space public parking facility, so city and county zoning rules directly affect how much space can be leased and how the site can be used.
Public-access, building, and parking rules can raise compliance costs fast, especially when local officials tighten use permits or change occupancy limits. One city decision can alter tenant mix, foot traffic, and rental demand.
- 800 public parking spaces shape tenant access
- Local zoning controls allowable uses
- Public-use rules affect leasing flexibility
- City and county policy can lift costs
For Rafael Holdings, Inc., political risk is less about federal policy and more about local approvals, inspections, and rule changes that can delay leasing or require added spend.
FDA and Policy Risks Weigh on Rafael Holdings
Rafael Holdings faces high political risk from FDA oncology oversight, because its CPI-613 program still needs U.S. review to reach approval. Cross-border exposure also matters: U.S.-Israel goods trade topped $50 billion in 2024, so policy friction can hit operations and sentiment. New Jersey tax and zoning rules can also lift costs and delay leasing.
| Political factor | Data point | Why it matters |
|---|---|---|
| FDA oversight | 2 Phase III trials | Approval timing risk |
| U.S.-Israel trade | $50B+ in 2024 | Cross-border exposure |
| New Jersey tax | 11.5% | Higher operating cost |
What is included in the product
Detailed Word Document
Analyzes how Political, Economic, Social, Technological, Environmental, and Legal forces shape Rafael Holdings, Inc.’s risks, opportunities, and strategy.
Customizable Excel Spreadsheet
A concise Rafael Holdings, Inc. PESTLE snapshot for fast risk review and easy sharing in planning meetings.
Reference Sources
Provides a concise, traceable sources list linking each key claim to industry reports, datasets, and benchmarks to speed due diligence and boost model credibility.
Economic factors
Commercial office leasing revenue
Rafael Holdings, Inc.’s office leasing income depends on occupancy and lease rates, so weak demand can cut rent and lift vacancy risk. U.S. office vacancy stayed near 19% in 2025, still pressuring owners with rent resets and longer leasing cycles. Stronger leasing terms lift recurring cash flow and make the real estate unit more stable.
Capital-intensive clinical development
Pharmaceutical development is brutally capital-heavy: a single Phase III trial can run for years and enroll hundreds to thousands of patients, while R and D spends often tops 15% to 20% of revenue in drug developers. Rafael Holdings, Inc. faces that same squeeze because two Phase III registrational studies must be funded before any product sales begin. That makes access to equity, debt, or strategic capital critical, especially when cash burn rises faster than revenue.
Biotech valuation and financing cycles
Biotech valuations stay tied to risk appetite: when rates remain high, early-stage drug assets usually face lower multiples and tougher fundraises. In 2025, the Federal Reserve kept rates in the 4.25% to 4.50% range, which still pressured higher-risk capital and made clinical-stage financing more selective. For Rafael Holdings, Inc., that can slow asset re-pricing and raise dilution risk if follow-on funding comes at weaker terms.
Interest-rate pressure on real estate
Higher rates kept refinancing costs elevated, with the U.S. 10-year Treasury near 4% in 2025, and that feeds straight into commercial real estate cap rates and valuations. For Rafael Holdings, Inc., that can squeeze asset income and lower net asset value when debt resets or property values are marked down.
- Higher debt service cuts cash flow.
- Cap rates rise, values fall.
- Net asset value can drop fast.
That makes leverage and lease renewals more sensitive to every rate move.
USD and ILS currency exposure
Rafael Holdings, Inc. faces USD and ILS exposure because it holds operations and investments in the United States and Israel. A move in USD/ILS can lift or reduce the U.S. dollar value of Israeli assets and liabilities, even when local performance is stable. In 2025, this matters more because Israel-linked costs and receipts are often settled in shekels, while reporting is in dollars.
- USD/ILS moves change reported asset values.
- Shekel costs can rise in dollar terms.
- Hedging can reduce, not remove, volatility.
Higher Rates and Office Weakness Pressure Rafael Holdings
Higher rates still matter most for Rafael Holdings, Inc.: the Fed held 4.25% to 4.50% in 2025 and the U.S. 10-year stayed near 4%, keeping debt and cap rates high. Office vacancy near 19% in 2025 also kept leasing pressure on rent and renewals. Biotech funding stayed selective, so Phase III spending raises dilution risk. USD/ILS swings can also move reported value.
| Factor | 2025 data | Effect |
|---|---|---|
| Fed funds | 4.25%-4.50% | Higher funding cost |
| 10-year U.S. Treasury | Near 4% | Higher cap rates |
| Office vacancy | Near 19% | Weak rent growth |
Preview the Actual Deliverable
Rafael Holdings, Inc. PESTLE Analysis
The preview shown here is the exact Rafael Holdings, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use, with no placeholders or surprises.
Sociological factors
Advanced pancreatic cancer unmet need
In the U.S., pancreatic cancer has about a 13% 5-year relative survival rate, so patients and oncologists keep looking for better options. CPI-613’s trial in advanced pancreatic cancer can benefit from this unmet need, which can support enrollment and, if data are strong, future adoption. High mortality also keeps caregiver and advocacy attention high.
Relapsed refractory AML burden
Rafael Holdings, Inc.'s lead candidate targets relapsed or refractory AML, where many patients have few options and survival stays poor. AML causes about 20,800 new U.S. cases and 11,200 deaths a year, and relapsed/refractory cases often need new therapies fast. That keeps social demand for better oncology drugs high, even as treatment gaps remain wide.
Aging population in major markets
Cancer incidence rises with age, so aging in major markets supports Rafael Holdings, Inc.’s oncology demand. The United States had about 59 million people aged 65 and older in 2024, and Israel had roughly 1.2 million, widening the patient pool for cancer care. This trend can also support the pharmaceutical pipeline as older populations need more long-term treatment options.
Hospital and trial enrollment behavior
Clinical success hinges on patients agreeing to join trials, and physician referrals plus hospital site support can speed or stall enrollment. When enrollment slows, readouts slip and trial burn rises, which matters for Rafael Holdings, Inc.'s cash use and timelines.
- Patient consent drives trial pace.
- Physician referrals shape site flow.
- Slow enrollment delays data and raises costs.
Post-pandemic office usage patterns
Post-pandemic office use still reflects hybrid work, with U.S. office vacancy near 19.9% in Q2 2024, which keeps leasing demand uneven for Rafael Holdings, Inc. Social preferences now favor flexible space, strong amenities, and transit-friendly locations, not just square footage.
That shift matters because tenants are more selective, so older or less central buildings face weaker pricing power. Kastle Systems’ office swipes have also stayed around half of pre-pandemic levels in many big-city markets, showing that attendance remains below 2019 norms.
- Hybrid work trims daily office demand
- Flexibility now ranks above size
- Quality and location drive renewals
- Leasing risk rises for weak assets
Why Aging Demand Supports Rafael as Office Weakness Persists
An aging, high-cancer-burden patient base supports Rafael Holdings, Inc., but trial uptake still depends on physician referrals, caregiver support, and patient trust. U.S. office demand stays selective too: vacancy was 19.9% in Q2 2024, so social preference for flexible, amenity-rich space still hurts weaker assets.
| Factor | Latest data |
|---|---|
| U.S. 65+ | 59M, 2024 |
| Israel 65+ | 1.2M, 2024 |
| U.S. office vacancy | 19.9%, Q2 2024 |
Technological factors
CPI-613 devimistat metabolic oncology platform
CPI-613, now called devimistat, is Rafael Holdings, Inc.'s lead metabolic oncology asset and aims at energy pathways that differ between healthy and malignant cells. That makes it a niche cancer platform, but its value still depends on clear clinical proof and durable efficacy. In biotech terms, the science is the asset; the trial data sets the price.
2 pivotal Phase III registrational studies
Rafael Holdings, Inc. has 2 Phase III registrational studies, so trial tech is a make-or-break factor. Late-stage work depends on eClinical tools like electronic data capture, central monitoring, and real-time analytics to keep data clean and on time.
In Phase III, even small system errors can delay readouts or weaken trial integrity, and that can push back regulatory filing plans. Strong data systems help protect the timeline and the value of both programs.
With 2 late-stage trials running, Rafael Holdings, Inc. needs reliable tech control across sites, vendors, and patient data.
Clinical trial data and biomarker analytics
Modern oncology trials need clean data, because FDA review for drug approvals depends on auditable endpoints and biomarker readouts. Biomarker-led trials can narrow patient groups and raise response rates; for example, tumor-agnostic drugs like Keytruda and Vitrakvi rely on genomic signals. Better analytics can cut delays, strengthen submissions, and support Rafael Holdings, Inc.'s oncology pipeline.
Drug development manufacturing controls
Rafael Holdings, Inc. depends on scalable manufacturing to move a clinical candidate into a market product, and that step drives both cost and approval speed. FDA drug GMP inspections rose to 625 in FY2025, showing how tight process control, stability testing, and quality systems can decide readiness. Strong controls also reduce batch failures and help keep COGS in check.
- Scalable plants cut transfer risk.
- Stability data supports shelf life.
- Quality systems speed FDA review.
Building systems and parking operations
Rafael Holdings, Inc. benefits from an integrated 800-space public parking facility, so building systems and parking tech matter for both tenant flow and asset use. Smart automation, security, and parking management can cut operating friction and improve the tenant experience. With tighter control of access, lighting, and space turnover, the property can lift utilization and trim costs.
- 800-space public parking asset
- Automation lowers operating waste
- Security tech supports tenant comfort
- Parking systems improve space use
Rafael's Edge: Trials, GMP Discipline, and Parking Tech
Rafael Holdings, Inc.'s tech edge rests on devimistat and two Phase III trials, where eClinical tools, clean data capture, and central monitoring can make or break readouts.
In FY2025, FDA drug GMP inspections reached 625, underscoring how quality systems, stability data, and process control shape approval speed and COGS.
Its 800-space parking asset also needs smart access, security, and space-use tech to lift utilization and trim operating friction.
| Factor | Data |
|---|---|
| Phase III trials | 2 |
| FDA GMP inspections FY2025 | 625 |
| Parking spaces | 800 |
Legal factors
FDA investigational drug compliance
CPI-613 remains in clinical development, so Rafael Holdings, Inc. must stay aligned with FDA investigational drug rules under 21 CFR Part 312, including IND filings, safety reports, and protocol updates. Any missed adverse-event reporting or trial deviation can trigger a clinical hold and slow enrollment. With one asset still dependent on trial execution, even a small compliance lapse can disrupt timelines and value.
Phase III registrational evidence standards
Rafael Holdings, Inc. faces a high bar in Phase III because the FDA can lean on two pivotal trials, and each one must be adequate and well controlled. Registrational studies are built to support approval decisions, so clean endpoints, prespecified stats, and low bias matter legally. In practice, a primary endpoint usually needs strong significance, often p<0.05, or the case gets weaker fast.
SEC reporting as a public company
Rafael Holdings, Inc. is a public issuer, so it must file SEC reports like Form 10-K and 10-Q, plus timely 8-K updates under U.S. securities laws. That means financial reporting, risk disclosure, and governance controls are ongoing legal duties, not one-time tasks. Any weakness in disclosure controls can raise enforcement, restatement, and shareholder liability risk.
Patent and exclusivity protection
Rafael Holdings, Inc. needs strong patent and exclusivity protection because its pharmaceutical value rests on intellectual property. In the US, a patent can run 20 years from filing, while FDA exclusivity can add 5 years for a new chemical entity, 7 years for orphan drugs, or 12 years for biologics. If those rights lapse, competitors can enter fast and cut commercialization value.
- Patent loss cuts pricing power.
- Exclusivity delays generic entry.
- IP strength drives pharma valuation.
Commercial lease and property law
Rafael Holdings, Inc.'s real estate income depends on lease terms, landlord-tenant law, and property safety compliance; lease enforcement and code breaches can cut rent flow and raise repair costs. The public parking facility adds slip, trip, access, and insurance exposure, so access control and maintenance records matter. In 2025, the U.S. Census Bureau showed national office vacancy near 20%, which keeps lease legal discipline important.
- Lease terms drive cash flow stability
- Safety rules limit liability claims
- Parking access raises duty-of-care risk
- Compliance protects asset income
Rafael Holdings: FDA, SEC, and Patent Risks Can Move Value Fast
Rafael Holdings, Inc. faces tight FDA, SEC, and patent rules, so legal risk is tied to trial conduct, disclosure quality, and IP life. A missed adverse-event filing under 21 CFR Part 312 can trigger a clinical hold, while public-company reporting errors can raise enforcement risk. Patent loss can cut value fast; U.S. patents last 20 years from filing.
| Legal factor | Key risk data |
|---|---|
| FDA trials | IND reporting, safety updates |
| SEC reporting | 10-K, 10-Q, 8-K duties |
| Patent life | 20 years from filing |
Environmental factors
Office building energy consumption
Office buildings are energy-hungry assets: U.S. buildings drive about 40% of energy-related carbon emissions, and HVAC plus lighting are the main loads. For Rafael Holdings, Inc., higher utility rates and tighter emission rules can lift operating expenses, while better insulation, controls, and efficient HVAC can protect margins. Cutting energy use by 10% can quickly improve net operating income.
HVAC and indoor air quality standards
Tenant health and comfort at Rafael Holdings, Inc. depend on strong ventilation, filtration, and humidity control, and the EPA says indoor air can be 2 to 5 times more polluted than outdoor air. Indoor air quality now weighs more in office leasing, with better HVAC helping meet standards such as ASHRAE 62.1 and supporting healthier spaces. Better systems can lift occupancy and retention, especially as tenants keep favoring buildings with cleaner air and lower sick-building risk.
800-space parking footprint
Rafael Holdings, Inc.’s 800-space public parking footprint raises site intensity and can add idle-time emissions, especially if demand stays high. Transportation still makes up about 28% of U.S. greenhouse gas emissions, so parking-heavy assets face real air-quality and congestion pressure. That can push the Company toward EV chargers, lighting upgrades, and traffic-flow controls to meet stricter environmental expectations.
Climate risk in New Jersey and Israel
Rafael Holdings, Inc. has assets in New Jersey and Israel, two regions facing sharp climate stress. New Jersey coastal flooding has worsened as sea level at Atlantic City has risen about 1.6 feet since 1911, while Israel has seen hotter, drier conditions and more heat strain on buildings and systems.
That raises operating and maintenance costs, and it can disrupt access, cooling, and utilities. Resilience planning matters for continuity and insurance, especially as insurers price in flood, fire, and extreme-heat risk.
- New Jersey: flood and storm exposure
- Israel: heat and water stress
- Higher maintenance and outage risk
- Insurance and continuity planning matter
Investor ESG expectations
Investor ESG expectations are rising as public companies face tighter scrutiny on environmental performance, and buildings are a big focus because they drive about 34% of global energy demand and 37% of energy-related CO2 emissions. For Rafael Holdings, Inc., real estate energy use, utility costs, and asset-level footprint can affect investor sentiment, loan terms, and valuation. ESG gaps can also hurt reputation, while better disclosure and lower-emission operations can support access to capital.
- Buildings drive 37% of energy-related CO2
- Energy use now shapes investor reviews
- ESG can move financing terms and trust
Rafael Holdings Faces Rising Climate Costs From Buildings, Floods, and Heat
Rafael Holdings, Inc. faces climate risk from energy use, flood exposure, and indoor air demands: buildings still drive about 37% of energy-related CO2, and the EPA says indoor air can be 2 to 5 times dirtier than outdoor air. New Jersey flooding and Israel heat stress can raise repair, utility, and insurance costs, while EV-ready parking and efficient HVAC can help protect occupancy and margins.
| Factor | Key data |
|---|---|
| Buildings | 37% of energy-related CO2 |
| Indoor air | 2 to 5x more polluted |
| Transport | 28% of US GHG emissions |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.